Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...

Drug Administration and Therapy Phases: Overview

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evaluating the potential of fast healthcare interoperability resources for clinical registry data submission.

Journal of the American Medical Informatics Association : JAMIA·2026

Same author

Building Real-World Evidence Infrastructure to Improve Health and Healthcare in the United States: Part III-Questions for Translational Science and Action Theory.

International journal of translational medical research and public health·2026

Same author

Building Real-World Evidence Infrastructure to Improve Health and Healthcare in the United States: Part II-How Coordinated Registry Networks Operate Like Systemic Coordinated Inter-Organizational Networks.

International journal of translational medical research and public health·2026

Same author

Building Real-World Evidence Infrastructure to Improve Health and Healthcare in the United States: Part I-Coordinated Registry Networks and Systemic Coordinated Inter-Organizational Networks.

International journal of translational medical research and public health·2026

Same author

Framework for Improving Patient Safety: Reference Model for FHIR-Enabled, Patient-Centric Home Medication List Management and Medication Reconciliation.

Applied clinical informatics·2025

Same author

The high price of equity in pulse oximetry: A cost evaluation and need for interim solutions.

PLOS digital health·2024

Same journal

Correction: Low-Dose Naltrexone: What is the Evidence? A Narrative Review.

Advances in therapy·2026

Same journal

Usability and Acceptance of Autoinjector and Prefilled Syringe Devices by Patients with Generalized Myasthenia Gravis in a Human Factors Study.

Advances in therapy·2026

Same journal

Treatment Patterns and Decision Drivers in Chinese Patients with Locally Advanced Cervical Cancer: Results from a National Physician Survey.

Advances in therapy·2026

Same journal

Matching-Adjusted Indirect Comparison of Tarlatamab for Patients with Platinum-Refractory or Platinum-Resistant Extensive-Stage Small-Cell Lung Cancer.

Advances in therapy·2026

Same journal

Sacral Neuromodulation for Refractory Overactive Bladder: Closing the Gaps in Anatomy, Mechanisms, and Parameter Selection.

Advances in therapy·2026

Same journal

Exploring the Impact of Delivering Allergy Medication as Self-Care on Healthcare Greenhouse Gas Emissions in the United Kingdom.

Advances in therapy·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Prasugrel: Clinical development and therapeutic application.

Daniel R Guerra¹, James E Tcheng

¹Cardiac Study Center, Tacoma, WA 98405, USA. danielreneguerra@yahoo.com

Advances in Therapy

|December 19, 2009

Summary

This summary is machine-generated.

Dual antiplatelet therapy using aspirin and clopidogrel is standard for acute coronary syndromes. Prasugrel offers an alternative with improved efficacy but increased bleeding risk, now approved for specific patient groups.

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Related Experiment Videos

Last Updated: Jun 17, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Area of Science:

Cardiology
Pharmacology
Internal Medicine

Background:

Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is standard for acute coronary syndromes (ACS) and percutaneous coronary intervention (PCI).
Clopidogrel, a P2Y12 inhibitor, has limitations in efficacy and response variability.
Newer agents aim to overcome these limitations while managing bleeding risks.

Purpose of the Study:

To review the limitations of current antiplatelet therapy, specifically clopidogrel.
To discuss the pharmacologic profile and clinical application of prasugrel.
To highlight prasugrel's role in managing thrombotic cardiovascular events in ACS patients undergoing PCI.

Main Methods:

Review of existing literature on antiplatelet agents.
Analysis of data from large, randomized clinical trials involving prasugrel.
Discussion of pharmacologic characteristics and clinical trial outcomes.

Main Results:

Prasugrel demonstrates pharmacologic advantages over clopidogrel in overcoming limitations.
Large trials show prasugrel reduces thrombotic cardiovascular events in ACS patients undergoing PCI.
Increased bleeding risk is associated with prasugrel compared to clopidogrel.

Conclusions:

Prasugrel is a valuable third-generation thienopyridine antiplatelet agent.
Its approval by the FDA signifies its role in specific ACS patient populations undergoing PCI.
Balancing efficacy and bleeding risk is crucial in selecting antiplatelet therapy.